OverviewSuggest Edit

Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia, and CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults. Besides, the Company provides Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults, and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.

TypePublic
Founded1995
HQNewark, US
Websiteassertiotx.com

Latest Updates

Employees (est.) (Dec 2018)116(-31%)
Revenue (FY, 2018)$311.8 M(-18%)
Share Price (Jun 2019)$3.1 (+4%)

Key People/Management at Assertio Therapeutics

Arthur J. Higgins

Arthur J. Higgins

President and Chief Executive Officer
Mark D. Booth

Mark D. Booth

Senior Vice President, General Manager Specialty Business Unit
Stan Bukofzer

Stan Bukofzer

Senior Vice President, Chief Medical and Scientific Officer
Phillip B. Donenberg

Phillip B. Donenberg

Chief Financial Officer and Senior Vice President
Matthew M. Gosling

Matthew M. Gosling

Senior Vice President and General Counsel
Sharon D. Larkin

Sharon D. Larkin

Senior Vice President, Human Resources and Administration
Show more

Assertio Therapeutics Office Locations

Assertio Therapeutics has an office in Newark
Newark, US (HQ)
7999 Gateway Blvd STE 300
Show all (1)

Assertio Therapeutics Financials and Metrics

Assertio Therapeutics Revenue

Embed Graph
View revenue for all periods
Assertio Therapeutics's revenue was reported to be $311.77 m in FY, 2018
USD

Revenue (Q2, 2019)

57.2m

Gross profit (Q2, 2019)

55.1m

Gross profit margin (Q2, 2019), %

96.3%

Net income (Q2, 2019)

(13.6m)

EBIT (Q2, 2019)

3.6m

Market capitalization (10-Jun-2019)

199.0m

Closing stock price (10-Jun-2019)

3.1

Cash (30-Jun-2019)

68.3m
Assertio Therapeutics's current market capitalization is $199 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

134.2m390.4m342.7m455.9m380.7m311.8m

Revenue growth, %

191%(12%)33%

Cost of goods sold

7.1m15.1m67.9m87.4m72.6m18.5m

Gross profit

127.1m375.2m274.8m368.5m308.1m293.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

37.5m76.5m67.7m51.5m32.2m94.5m104.9m104.8m116.7m110.5m90.4m100.5m95.4m128.4m63.3m77.5m57.9m57.2m

Cost of goods sold

1.8m3.7m4.7m3.5m3.1m22.9m20.9m23.5m21.0m20.2m17.8m19.7m17.4m12.0m2.8m3.0m2.6m2.1m

Gross profit

35.7m72.8m63.1m48.0m29.1m71.6m83.9m81.2m95.7m90.3m72.7m80.7m78.0m116.4m60.5m74.5m55.4m55.1m

Gross profit Margin, %

95%95%93%93%90%76%80%78%82%82%80%80%82%91%96%96%96%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

244.7m488.7m101.1m117.7m126.9m110.9m

Accounts Receivable

11.5m27.0m71.1m102.1m71.9m37.2m

Inventories

10.1m8.5m10.5m13.0m13.0m3.4m

Current Assets

337.0m617.6m309.0m306.2m230.9m208.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

43.3m131.8m(75.7m)(88.7m)(102.5m)36.9m

Depreciation and Amortization

6.2m12.0m85.7m109.4m105.5m106.4m

Inventories

4.3m1.7m9.3m(3.7m)(1.9m)9.0m

Accounts Payable

16.0m(2.7m)(2.7m)(1.6m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

17.9m30.7m37.1m(11.6m)(33.3m)(45.1m)(20.9m)(31.5m)(44.4m)(26.7m)(53.4m)(69.4m)33.8m12.8m61.0m(14.3m)(27.9m)

Depreciation and Amortization

3.0m6.1m9.1m2.5m30.3m57.9m27.7m55.3m83.0m26.3m52.7m79.0m26.9m53.8m80.7m26.0m51.5m

Inventories

7.8m1.7m2.4m2.9m6.5m9.2m7.5m(761.0k)(346.0k)(1.5m)873.0k490.0k272.0k7.5m7.8m8.5m(40.0k)195.0k

Accounts Payable

18.2m13.8m(2.3m)(2.9m)(4.9m)(2.4m)(2.7m)(4.6m)(2.1m)(938.0k)(3.0m)(2.9m)(2.5m)
USDY, 2019

Financial Leverage

4.1 x
Show all financial metrics

Assertio Therapeutics Online and Social Media Presence

Embed Graph

Assertio Therapeutics News and Updates

Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021

LAKE FOREST, Ill., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) (“Assertio”) today announced it has entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of holders of Assertio’s currently outstanding 2.50%…

Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019

LAKE FOREST, Ill., April 24, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019, after the close of markets. Following the announcement, the Company will host a conference call begin…

Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling

LAKE FOREST, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Assertio with respect to the company’s patent litigation against three filers of Abbreviated New Dr…

Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results

-- Reports Neurology Franchise Annual Net Sales of $110.3 million, at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance --

Assertio Therapeutics Announces the Appointment of Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018

LAKE FOREST, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that Phillip B. Donenberg, Senior Vice President and Chief Financial Officer, will retire effective November 30, 2018. Replacing Mr. Donenberg will be Daniel A. Peisert, who has been app…

Global Pain Management Drugs 2018-2025 Pfizer, GSK, Grunenthal, Bayer, Sanofi, Eli Lilly, AstraZeneca, Endo, Merck, Depomed, Yunnan Baiyao, Teva, J&J, Allergan, Purdue

Latest Report Available at Analytical Research Cognizance ,Pain Management Drugs Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth. Posted via Industry Today. Follow us on Twitter @Indust…
Show more

Assertio Therapeutics Blogs

Assertio Therapeutics to Report Third-Quarter 2018 Financial Results After The Close of Markets on Thursday, November 8, 2018

LAKE FOREST, Ill. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2018 financial results on Thursday, November 8, 2018 , after the close of markets. Following the announcement, the Company will host a conference call

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Content Import Wed, 08/08/2018 - 22:37 Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 6, 2018 at 4:05 PM EDT This release is a backfill from a News Wire …

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 Content Import Wed, 08/08/2018 - 22:37 Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 July 9, 2018 at 8:31 AM EDT This release is a backf…

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical

Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical Content Import Wed, 08/08/2018 - 22:37 Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical December 4, 2017 at 4:31 PM EST This release is a b…

Arthur J. Higgins

Arthur J. Higgins deborah.drisco… Thu, 07/26/2018 - 23:10 Arthur J. Higgins

Assertio Therapeutics Frequently Asked Questions

  • When was Assertio Therapeutics founded?

    Assertio Therapeutics was founded in 1995.

  • Who are Assertio Therapeutics key executives?

    Assertio Therapeutics's key executives are Arthur J. Higgins, Mark D. Booth and Stan Bukofzer.

  • How many employees does Assertio Therapeutics have?

    Assertio Therapeutics has 116 employees.

  • What is Assertio Therapeutics revenue?

    Latest Assertio Therapeutics annual revenue is $311.8 m.

  • What is Assertio Therapeutics revenue per employee?

    Latest Assertio Therapeutics revenue per employee is $2.7 m.

  • Who are Assertio Therapeutics competitors?

    Competitors of Assertio Therapeutics include Collegium Pharmaceutical, Insys Therapeutics and MannKind Corporation.

  • Where is Assertio Therapeutics headquarters?

    Assertio Therapeutics headquarters is located at 7999 Gateway Blvd STE 300, Newark.

  • Where are Assertio Therapeutics offices?

    Assertio Therapeutics has an office in Newark.

  • How many offices does Assertio Therapeutics have?

    Assertio Therapeutics has 1 office.